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Abstract
We recently showed that bitter melon-derived triterpenoids (BMTs) activate AMPK and increase GLUT4 translocation to the
plasma membrane in vitro, and improve glucose disposal in insulin resistant models in vivo. Here we interrogated the
mechanism by which these novel compounds activate AMPK, a leading anti-diabetic drug target. BMTs did not activate
AMPK directly in an allosteric manner as AMP or the Abbott compound (A-769662) does, nor did they activate AMPK by
inhibiting cellular respiration like many commonly used anti-diabetic medications. BMTs increased AMPK activity in both L6
myotubes and LKB1-deficient HeLa cells by 20–35%. Incubation with the CaMKKb inhibitor, STO-609, completely attenuated
this effect suggesting a key role for CaMKKb in this activation. Incubation of L6 myotubes with the calcium chelator EGTA-
AM did not alter this activation suggesting that the BMT-dependent activation was Ca2+-independent. We therefore
propose that CaMKKb is a key upstream kinase for BMT-induced activation of AMPK.
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Introduction
Type 2 diabetes (T2D) accounts for 90% of the world’s
escalating diabetes problem, with 439 million people expected
to have diabetes by 2030 [1] at a predicted global healthcare
cost of US $490 billion per annum [2]. However, current
treatments for T2D, insulin resistance and obesity remain
insufficient and often result in undesirable side-effects [3].
Traditional medicines have been an attractive source of novel
anti-diabetic therapeutics. One such source is the bitter melon
(BM, Momordica charantia) with extracts having been used to treat
diabetes-like symptoms in humans for hundreds of years. Bitter
melon extracts have been reported to have hypoglycaemic,
hypolipidemic, antioxidant and anti-inflammatory effects and
improve skeletal muscle insulin signalling in vivo [4–7]. Our
recent studies have revealed that bitter melon-derived triterpe-
noids (BMTs) can increase fat oxidation and glucose tolerance
in vivo and stimulate glucose transporter 4 (GLUT4) transloca-
tion via the activation of AMP-activated protein kinase (AMPK)
in both muscle and fat cells [8]. Furthermore, we have recently
demonstrated a sustained efficacy of a triterpenoid in eliminat-
ing hyperglycaemia in T2D mice [9]. These reports suggest that
triterpenoids may be an attractive source of new anti-diabetic
therapeutics via activating AMPK.
AMPK is a potential target for the treatment of T2D as
activation of this kinase can promote fat oxidation to counteract
insulin resistance [10–12]. AMPK activation is associated with the
actions of anti-diabetic drugs including metformin and thiazolidi-
nediones (TZDs, such as rosiglitazone and pioglitazone). However,
there are limitations to these treatments. Metformin is not
sufficient in the long term to control hyperglycemia and concerns
have been raised about cardiac complications associated with
TZDs [13,14]. One common feature of metformin and rosiglita-
zone is that both activate AMPK indirectly by inhibiting
mitochondrial Complex I [15]. A similar effect has also been
found with other AMPK-activating agents such as berberines
[15,16] and resveratrol [17]. Conceivably, activation of AMPK
without disturbing mitochondrial respiration may be a preferred
mechanism to avoid some of the side-effects of these anti-diabetic
agents [18,19].
AMPK is a heterotrimer consisting of a catalytic a subunit, a
scaffolding b subunit [10–12,20] and regulatory c subunit, which
is responsible for binding adenosine nucleotides, AMP, ADP and
ATP [21,22]. AMPK is activated in response to changes in the
adenylate charge [23], leading to an increase in AMP- or ADP-
associated AMPK and phosphorylation by the major upstream
kinases LKB1 [24] or CaMKKb [25,26]. LKB1-mediated
activation of AMPK is dependent on binding to MO25a and
STRADa, which regulates its subcellular localisation [27].
CaMKK, has two isoforms (a and b) with CaMKKb considered
the major AMPK kinase due to its ability to directly bind to
AMPK which then directs its kinase activity away from its other
substrates and towards AMPK [28]. Phosphorylation inhibits the
autonomous activity of CaMKKb which is relieved by Ca2+/CaM
binding [29].
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The purpose of this study was to identify the mechanism by
which BMTs increase AMPK phosphorylation. Our results in the
present study rule out direct allosteric activation, as well as indirect
activation of AMPK through inhibition of mitochondrial respira-
tion. We used LKB1-deficient HeLa cells together with the
CaMKKb inhibitor and calcium chelators to confirm that BMTs
activate AMPK through CaMKKb activation without altering
intracellular calcium flux. These data support BMTs as being a
novel class of AMPK activators and advocates the CaMKK-
AMPK pathway as a potential target for novel anti-diabetic
therapeutics.
Materials and Methods
Column chromatographic separations were carried out by using
silica gel H60 (300–400 mesh, Qingdao Haiyang Chemical Group
Corporation, China), MCI GEL CHP20P (75–150 mm, Mitsu-
bishi, Japan), and Sephadex LH-20 (Pharmacia Biotech AB,
Sweden) as packing materials. HSGF254 silica gel TLC plates
(Yantai Chemical Industrial Institute, China) were used for
analytical TLC. The Analytical HPLC system was composed of
Waters 2690 separations module, Waters 996 diode array detector
(Waters, USA), and All-Tech 2000 ELSD. A LiChrospher
100 RP-18e column (12564 mm i.d.; particle size 5 mm) was
used for the separation. The Preparative HPLC system composed
of two PrepStar SD-1 solvent delivery modules, a ProStar UV-Vis
320 detector, and a ProStar 701 Fraction Collector (Varian, USA).
A LiChrospher 100 RP-18 (Merck, USA) column (220625 mm
i.d.; particle size 12 mm) was used for isolation. 5-Aminoimidazole-
4-carboxamide-1-b-D-ribofuranoside (AICAR) was obtained from
Toronto Research Chemicals (Ontario, Canada), STO-609
acetate was from Tocris Bioscience (Bristol, UK), EasyTide
[c-32P] ATP (10 mCi/ml) was from Perkin Elmer (Boston, MA,
USA), AMARA peptide was from Auspep (Vic, Australia);
ionomycin (calcium salt), bovine serum albumin (BSA), a-MEM,
DMEM, foetal bovine serum (FBS) and 1006antibiotic/antimy-
cotic and Pen/Strep/Glutamine (PSG) were from Invitrogen
(Auckland, NZ). EGTA-AM was from Calbiochem (La Jolla, CA,
USA) and Abbott compound (A-769662) was a gift from Kei
Sakamoto (Dundee, UK). The pan-AMPKb antibody was a gift
from David Carling (London, UK). The 14-3-3b, CaMKI pT177
and total antibodies were from Santa Cruz Biotechnology Inc.
(CA, USA); all other antibodies were from Cell Signaling
Technologies (Beverly, MA, USA).
Purification of Tetracyclic Triterpenoids from Bitter Melon
Purification of BMT-1 has been described previously [8].
Briefly, an initial ethanol extraction was obtained from freeze-
dried bitter melon extracted with 80% aqueous ethanol, and
then partitioned with dichloromethane and n-butanol, succes-
sively. The n-butanol soluble part was subjected to macroporous
resin column chromatography eluting with ethanol/water
mixture with various volume ratios to produce different
subfractions. Based on preliminary tests in animals, one selected
subfraction was then subjected to normal phase silica gel
column chromatography with gradient elution (CHCl3: MeOH
100:7,100:35) to yield 8 fractions. BMT-1 was purified from
fraction 6 by repeated column chromatography over MCI gel
(MeOH in water 40,95%), silica gel (CHCl3: MeOH 8:1,8:3),
and Sephadex LH-20 (MeOH). BMT-17 was also purified from
this subfraction using repeated column chromatography over
silica gel (CHCl3: MeOH 12:1,5:1), Sephadex LH-20 (CHCl3:
MeOH 1:1), and finally preparative HPLC (CH3CN in water
45,70%, 90 min, 15 ml/min). The structure of BMT-17 was
determined by NMR spectroscopic data and its purity (.98%)
was determined by HPLC analysis. The structures of both
compounds can be seen in Fig. 1A. BMT-1 is soluble in
MeOH, pyridine and DMSO while BMT-17 is soluble in
chloroform and DMSO. As such both compounds were
solubilised in DMSO for this study.
Tissue Culture, Respiration and AMPK Assays
L6 myoblasts (up to passage 17) were cultured in a-MEM
supplemented with 10% heat-inactivated FBS and 1% antibiotic/
antimycotic. HeLa cells (ATCC) were cultured in DMEM (high
glucose) supplemented with 10% heat-inactivated FBS, 16PSG
(Gibco, Invitrogen). Both were kept at 37uC in a humidified 5%
CO2 incubator. For differentiation into myotubes, L6 cells were
cultured in a-MEM supplemented with 2% heat-inactivated FBS
and 1% antibiotic/antimycotic for 5–7 days before interventions.
Before acute treatments, cells were moved into serum-free media
for 18 hrs. Cells were then treated with either vehicle (0.1%
DMSO), 2 mM AICAR, or BMTs, at concentrations indicated in
the figures 1, 2, 3, 4, 5, for 30 min. As 1 mM ionomycin was toxic
to the cells after 30 min, we incubated cells with ionomycin for
10 min. Cells were then quickly washed twice in ice-cold PBS
before addition of lysis buffer (50 mM HEPES pH 7.4, 150 mM
NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 10%
glycerol, 1 mM DTT) containing phosphatase inhibitors (40 mM
NaF, 4 mM Na4P2O7, 2 mM Na3VO4) and 16 Complete
Protease Inhibitor Cocktail (Roche Applied Sciences, Indianapolis,
IN, USA). Lysates were then snap-frozen in liquid nitrogen and
stored at 280uC before use. Whole cell lysates were prepared by
clearing cell debris by centrifugation before quantification of
protein content by BCA (Pierce Technology, Rockford, IL, USA)
or Bradford (Bio-Rad Laboratories, Hercules, CA, USA) protein
assay.
For respiration experiments, L6 myotubes were cultured and
differentiated in an XF24 culture plate (Seahorse Bioscience,
Billerica, MA, USA). Differentiated L6 myotubes were then
serum-starved 18 hrs in unbuffered a-MEM pH 7.4 (Invitrogen
Cat No. 12000-022). Basal oxygen consumption rates (OCR) were
measured in triplicate cycles of mix (3 min), wait (2 min) and
measure (3 min). Repeated triplicate cycles were performed
following each consecutive dose-dependent addition of vehicle,
BMT-1, BMT-17 or berberine. For quality control, the OCRs
were compared to those of untreated myotubes over time and total
protein content of each well following the final measurement. To
normalise well-well variation, the basal OCR of each well was set
to 100% and the dose-dependent effects of each injection were
compared to this.
For in vitro AMPK assays, AMPK complexes were first isolated
by immunoprecipitation. Briefly, 50 mg of lysate was combined
with 0.5 ml anti-pan-AMPKb antibody (to ensure all complexes
were retained), 10 ml Protein A/G Sepharose (Amersham) and
700 ml of lysis buffer in the absence of protease inhibitor cocktail
and incubated rotating at 4uC for 2 h. The beads were then
washed in 700 ml lysis buffer, then in 700 ml HGE buffer (50 mM
Hepes pH 7.4, 10% glycerol, 0.1 mM EDTA) and excess fluid was
removed using a 30 G needle. The isolated AMPK was then
incubated in assay buffer (50 mM HEPES pH 7.4, 5% glycerol,
5 mM MgCl2 and 200 mM AMARA peptide) in the absence or
presence of 200 mM AMP. Assays were initiated by addition of
32P-ATP (200 cpm/pmole) at 30uC for 10–14 min. An aliquot of
each sample was spotted onto P81 paper and stopped in 1%
phosphoric acid. Incorporation of 32P into the AMARA peptide
was assessed by b-scintillation counter.
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Figure 1. Bitter melon triterpenoids (BMT) phosphorylate and activate AMPK in L6 myotubes. Structure of BMT-1 and BMT-17 (A).
Serum-starved L6 myotubes were treated with either vehicle (V), BMT-1 or BMT-17 at 1 or 10 mM, or 10 mM berberine, (BBR) for 30 min before lysis (B–
F). 10 mg of lysate was analysed by Western blot analysis (B) with densitometric analysis plotted relative to vehicle (V) within each experiment for
pT172 (C) and pACC (D). AMPK complexes were isolated from 50 mg of lysate by immunoprecipitation with a pan-AMPKb antibody before
Tetracyclic Triterpenoids Activate CaMKK
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Western Blot Analysis
After protein quantification, whole cell lysates were reduced in
Laemmli buffer containing 15 mM DTT at 65uC for 10 mins.
Lysates (10 mg of total protein) were then subjected to SDS-PAGE
on 9% gels and transferred onto Hybond PVDF membranes (GE
Healthcare, Buckinghamshire, UK) overnight at a constant
current (40 mA) in Tris/Glycine transfer buffer containing 10%
methanol. Membranes were then blocked in 2% BSA in TBS
containing 0.1% Tween 20 (TBST) for at least 1 hr before being
incubated in rabbit polyclonal antibodies overnight (,16 hrs) at
4uC. Membranes were then washed in TBST and then incubated
in HRP-conjugated donkey anti rabbit secondary antibody
(Jackson Immuno Research Laboratories, West Grove, PA,
USA) for 1–2 hrs at room temperature. Membranes were then
washed in TBST and proteins were visualised by ECL
(PerkinElmer, Waltham, USA) and exposed on X-ray film before
scanning and densitometric analysis using ImageJ (NIH, Bethesda,
MD, USA).
Statistical Analysis
Results are presented as means 6 SEM. When multiple doses
were used, individual compounds were compared to vehicle
control by one-way ANOVA using a Fisher’s Least Significant
Difference post-hoc test. When two separate treatments were
considered, individual two-way ANOVA analyses were used to
assess treatment effects and interactions between treatment effects,
followed by post hoc tests to compare each group to the vehicle
control group. An unpaired Student’s t-test was used to assess
statistical significance where one group was compared to vehicle
control. For each statistical consideration, p#0.05 was taken to
indicate a significant difference.
Results
BMTs Increase AMPK Phosphorylation and Activity
Initially we confirmed that the lead candidate from the original
study, BMT-1 [8], and a structurally similar but lower molecular
weight compound, BMT-17 (Fig. 1A), resulted in AMPKphosphor-
ylation inL6myotubes.At the same timeweassessed if this increase in
AMPK phosphorylation led to phosphorylation of the key AMPK
substrate ACC at Ser-79. Incubation of serum-starved L6 myotubes
with 1 mM and 10 mM of these BMTs increased both AMPK Thr-
172andACCSer-79phosphorylation, thoughnot to theextentof the
positive control berberine (Fig. 1B–D). To assess if these BMTs
increased in vitroAMPKactivity,we isolatedAMPKcomplexes from
these lysates using a pan-AMPKb antibody that recognizes the
conservedC-terminusofbothAMPKbsubunitsessential forcomplex
formation [30]. Both BMTs increased AMPK activity (15–50%)
though, again, not to the extent of the positive control berberine
(Fig. 1E).BMTsactivatedAMPKboth in theabsenceandpresenceof
the allosteric activator, AMP, to a similar degree. However, no
interaction was evident with a two-way ANOVA (Fig. 1F) indicating
that this activation was independent of and additive to AMP-
dependent activation.
BMTs do not Allosterically Activate AMPK
To assess if these BMTs could directly activate AMPK in vitro, in
an allosteric manner similar to AMP or to the recently described
compound A-769662 [31], we again isolated AMPK from
assessment by in vitro AMPK assay; in the presence (both E and F), or absence (F only) of 200 mM AMP. Data are means 6 SEM for 3–6 independent
experiments each containing 2–4 repeats. *p,0.05, **p,0.01 by one-way ANOVA to V; ##p,0.01 to V by Student’s unpaired t-test. 1F was analysed
by two-way ANOVA with h p,0.05 for compound effects, 1p,0.05 for AMP effects. No interaction between treatment groups was apparent.
doi:10.1371/journal.pone.0062309.g001
Figure 2. BMTs do not directly activate AMPK in isolated AMPK complexes. AMPK complexes were isolated from untreated 18 hr serum-
starved L6 myotube lysates by immunoprecipitation using a pan-AMPKb antibody. The isolated AMPK was then incubated in vitro with either vehicle
(V) alone, 10 mM BMT-17, BMT-1 or Abbott compound (A-769662) in the presence or absence of 200 mM AMP in AMPK assay buffer for 10 min at
30uC. The in vitro kinase assay was then initiated with the addition of 200 mM 32P-Mg.ATP and assayed for a further 10 min at 30uC. Incorporation of
the 32P into the substrate peptide was then assessed by beta scintillation counting. Data are means 6 SEM for 5 separate experiments. **p,0.01 for
compound effect, ##p,0.01 for AMP effects by two-way ANOVA. No interaction between treatment groups was apparent.
doi:10.1371/journal.pone.0062309.g002
Tetracyclic Triterpenoids Activate CaMKK
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untreated serum-starved L6 myotubes. The isolated AMPK was
then incubated in vitro with 10 mM BMT-1 or BMT-17 or Abbott
compound A-769662 in the presence or absence of 200 mM AMP
for 10 min at 30uC before initiation of the in vitro AMPK assay
with the addition of 32P.MgATP (Fig. 2). Unlike the allosteric
activators AMP or A-769662, neither BMT-1 nor -17 could
increase AMPK activity in vitro, nor could they enhance the AMP-
dependent activation of the complex. The reason why the Abbott
compound (A-769662) only mildly increased AMPK activation
may relate to the fact that L6 myotubes are derived from rat
skeletal muscle which should predominantly express a2b2-
containing AMPK complexes, which are more AMP- and less
Abbott compound-sensitive [32,33]. Furthermore, AMPK has
been shown to be both nucleotide- and Abbott compound-
insensitive with increased basal activity [11,32], which may also
contribute to the subtle increase in AMPK activity seen here.
Together, these data suggest that BMTs do not activate AMPK in
an allosteric manner similar to either AMP or the Abbott
compound, nor do they enhance AMP-dependence of the AMPK
complex.
BMTs do not Activate AMPK by Altering Cellular
Respiration
As BMTs did not activate AMPK directly, indirect mechanisms
for AMPK activation were investigated. We recently showed that
metformin, rosiglitazone and another natural product, berberine,
could activate AMPK by altering the cellular energy charge
through inhibiting Complex I of the mitochondrial respiratory
chain [15]. We therefore assessed the effect of BMTs on whole cell
respiration in L6 myotubes using a Seahorse Bioscience XF24
Extracellular Flux Analyzer (USA). BMTs did not affect whole cell
respiration, in contrast to berberine, which induced a dose-
dependent inhibition of respiration (Fig. 3). These data were
consistent with respiration experiments performed on isolated
mouse skeletal muscle mitochondria (data not shown). Together
these results indicate that unlike many commonly used anti-
diabetic therapeutic agents, BMTs do not activate AMPK by
altering cellular respiration.
BMTs Activate AMPK through CaMKKband not through
LKB1
As AMPK is phosphorylated and activated by AMPKK-
dependent phosphorylation, we assessed the involvement of the
AMPKKs in the BMT-dependent AMPK activation. The
predominant AMPKKs are LKB1 and CaMKKb. To evaluate
the involvement of LKB1, we assessed the ability of these BMTs to
increase AMPK phosphorylation and activity in LKB1-deficient
HeLa cells [24]. Both BMT-17 and BMT-1 acutely phosphory-
lated and activated AMPK in HeLa cells, suggesting that LKB1 is
not necessary for these BMT-dependent effects (Fig. 4A–C). To
assess if CaMKKb itself was responsible for the increase in AMPK
phosphorylation and activity, we pre-incubated the HeLa cells
with 1 mM of the cell-permeable CaMKK inhibitor, STO-609, for
15 min before incubation with the BMTs. Pre-incubation with
STO-609 completely blocked the BMT-dependent AMPK phos-
phorylation and activation confirming that CaMKKb activity was
essential for the BMT-dependent AMPK activation. The partial
inhibition of the ionomycin-dependent AMPK activation by STO-
609 is consistent with previous reports under these conditions
[26,34], while the minimal effects on AICAR-dependent activa-
tion can be attributed to STO-609 only attenuating one of the
multiple actions of AMP on AMPK activation [35]. Together this
suggests that activation of AMPK by BMTs involves CaMKKb.
As HeLa cells lack LKB1, we therefore investigated if inhibition
of CaMKKb could attenuate the BMT-dependent increase in
AMPK phosphorylation and activation in L6 myotubes, which
contain LKB1. Accordingly, L6 myotubes were pre-incubated
with or without 1 mM of the CaMKKb inhibitor STO-609 for
15 min before incubation with BMTs. As with the HeLa cells,
BMTs increased AMPK phosphorylation and activation and this
effect was significantly inhibited by STO-609 (Fig. 4D–F).
Figure 3. BMTs do not activate AMPK by inhibiting cellular respiration. Dose-dependent inhibition of the oxygen consumption rate in L6
myotubes by berberine (BBR, solid black line) but not by BMTs 17 (dotted grey line) or 1 (solid grey line) relative to vehicle (V) alone (DMSO, dotted
black line). Oxygen consumption rates were measured in low glucose DMEM using a Seahorse XF24 extracellular flux analyser at 37uC. Data are means
6 SEM (n= 7–8 per group over 2 independent experiments) and are expressed as a percentage of the basal rate (100%). **p,0.01 vs V by Student’s
unpaired t-test.
doi:10.1371/journal.pone.0062309.g003
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Collectively these findings indicate that BMTs activate AMPK
through CaMKKb and not through LKB1.
BMTs Activate CaMKKb in a Calcium-independent
Manner
To assess if the BMTs increased CaMKKb activity per se, we
investigated if BMTs could also increase phosphorylation of the
well-established CaMKKb substrate, CaMKI, at Thr-177.
Accordingly, L6 myotubes were incubated with increasing doses
of BMT-17 for 30 min before analysis by Western blot (Fig. 5A
and B). Indeed, BMT-17 dose-dependently increased CaMKI
Thr-177 phosphorylation along with AMPK and ACC phosphor-
ylation, indicating that BMTs activate AMPK by activating
CaMKKb.
As CaMKKb is regulated in part by Ca2+/CaM binding, we
then assessed whether BMTs activate CaMKKb by increasing
intracellular calcium levels. To do this L6 myotubes were pre-
incubated with or without 150 mM of the cell-permeable calcium
chelator, EGTA-AM, for 15 min before addition of BMT-17 and
assessment of AMPK activity. Accordingly, incubation of L6
myotubes with BMT-17 significantly increased the AMPK
activity. Pre-incubation with EGTA-AM to deplete the intracel-
lular calcium levels did not alter the BMT-17-induced AMPK
activation (Fig. 5C). Together these data suggest that BMTs
activate AMPK through CaMKKb in a Ca2+-independent
manner.
Discussion
Here we have interrogated the mechanism by which two lead
BMTs (1 and 17) phosphorylate and activate AMPK. Unlike AMP
and the Abbott compound A-769662, BMTs do not allosterically
activate AMPK and, unlike berberine and metformin, BMTs do
not alter cellular respiration. Use of the cell permeable CaMKKb
inhibitor STO-609 on both LKB1-deficient HeLa cells and L6
myotubes has demonstrated the key role of CaMKKb in this event
(Fig. 6). We therefore suggest that BMTs activate AMPK in a
distinct manner from other anti-diabetic medications.
Figure 4. Activation of AMPK involves CaMKKb and not LKB1. Serum-starved HeLa cells (A–C) or L6 myotubes (D–F) were pre-treated61 mM
STO-609 for 15 min before being incubated in either vehicle (0.1% DMSO), 2 mM AICAR, or 10 mM BMTs 17 or 1, for 30 min; or 1 mM ionomycin (Iono)
for 10 min before lysis. Whole cell lysates (10 mg) were analysed by Western blot analysis (A and D) and quantified by densitometry (B and E). AMPK
complexes were isolated by immunoprecipitation with a pan-AMPKb antibody and assayed by in vitro AMPK kinase assay (C and F). Incorporation of
32P into the AMARA substrate peptide was then assessed by b–scintillation counting. Data are means 6 SEM (n= 4–8 per group). *p,0.05, **p,0.01
for compound effects by two-way ANOVA; ##p,0.01 for STO-609 effects, {p,0.05, {{p,0.01 for interactions between treatment groups.
doi:10.1371/journal.pone.0062309.g004
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Figure 5. BMTs activate AMPK through CaMKK and not through intracellular Ca2+ changes. Serum-starved L6 myotubes were treated
with either vehicle (V) alone, BMT-17 at 0.1 mM, 1 mM or 10 mM for 30 min before lysis; 10 mg of lysate was then analysed by Western blot (A) and
quantified by densitometry (B). A representative blot is shown. Serum-starved L6 myotubes were pre-treated with either 150 mM EGTA-AM (+) or
diluent (-) for 15 min before then being treated with 10 mM BMT-17 or vehicle for a further 30 min before lysis. AMPK was then isolated from 50 mg
lysate by pan-AMPKb immunoprecipitation and assessed by AMPK in vitro kinase assay (C). Data are means relative to untreated vehicle control (V)6
SEM from 5 independent experiments. *p,0.05, **p,0.01 to V by one-way ANOVA.
doi:10.1371/journal.pone.0062309.g005
Tetracyclic Triterpenoids Activate CaMKK
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BMTs increased AMPK activity in the absence and presence of
AMP in an additive but not synergistic way suggesting the
activation of AMPK by BMTs involves a mechanism distinct from
that of AMP. Furthermore, unlike A-769662 and the allosteric
activator AMP, neither of the BMTs could activate AMPK in vitro
suggesting that the BMTs do not activate AMPK in a direct
manner. This finding alone is an attractive attribute in an anti-
diabetic therapy, as this would allow AMPK to remain responsive
to other physiological stimuli such as an exercise bout.
Metformin, rosiglitazone, berberine and resveratrol all activate
AMPK at least in part by inhibiting mitochondrial respiration
[15,17]. This results in an increase in the cytosolic AMP:ATP
ratio, leading to an indirect activation of AMPK. Conceivably, the
inhibition of mitochondrial respiration may account for some of
the undesirable side-effects associated with indirect AMPK
activation including lactic acidosis as a result of the associated
increase in glycolysis [18,19]. Conversely, BMTs do not activate
AMPK by inhibiting mitochondrial or whole cell respiration and
therefore may be more tolerated as anti-diabetic medications.
AMPK is also activated by phosphorylation by themajor AMPKKs,
LKB1 and CaMKKb. Using LKB1-deficient HeLa cells and LKB1-
proficient L6 myotubes together with the cell-permeable CaMKKb
inhibitor STO-609, we provide evidence to indicate that BMTs
activate AMPK through CaMKKb and not LKB1. As BMTs also
increased phosphorylation of another CaMKKb substrate, CaMKI,
this indicates that BMTs may activate CaMKKb itself and provides
further evidence that BMTs are unlikely to activate AMPK through a
direct interaction. Since binding to AMPK directs the CaMKKb
activity away from its other substrates CaMKI and CaMKIV [36], it is
therefore also unlikely that BMTs enhance the AMPK:CaMKKb
interaction. As CaMKKb and its substrate CaMKI are both activated
by Ca2+/CaM binding [37], we then used the cell-permeable calcium
chelator EGTA-AM to examine if Ca2+/CaM binding was involved in
the activation of AMPK by BMTs. The inability of EGTA-AM to
block the BMT-dependent AMPK activation demonstrated that the
BMT-dependent AMPK activation was independent of intracellular
calcium levels. Conceptually, the BMTs could be binding directly to
the Ca2+/CaMbinding site and thereby enhancing CaMKKb activity.
However, further experiments are needed to confirm this hypothesis.
CaMKII, another Ca2+/CaM sensitive kinase can be activated by
methionine oxidation or auto-phosphorylation which then maintains
the protein in an active conformation [38]. CaMKKb too can be
phosphorylated at its N-terminus by CDK5 and GSK3, which
regulates its Ca2+/CaM-independent autonomous activity [39]. This
phosphorylation event is inhibitory, however it can be overcome by
Ca2+/CaM binding. Therefore, BMTs could be increasing CaMKKb
activity by inhibiting phosphorylation by these proteins.
It is also unclear whether these BMTs can enter the cell to
interact with CaMKKb. BMTs could, in fact, signal via surface
receptors to increase CaMKKb activity. Indeed, bitter melon
extracts have been shown to be estrogen receptor (ER) agonists
[40], with activation increasing CaMKK and AMPK activities
[41]. Accordingly, agonism of the membrane bound ER homolog
GPR30 [42], a G-protein coupled receptor homolog, showed anti-
diabetic properties [43]. Alternatively, as BMTs are structurally
similar to bile acids [44], they could agonise the bile acid receptor
TGR5, another G-protein coupled receptor which has anti-
diabetic properties, though this has not been linked to CaMKKb
or AMPK activities [45]. It remains to be clarified whether BMTs
may signal through surface receptors.
Natural products may be metabolised by specialized enzymes of
living organisms to produce pharmacologically active metabolites.
Due to the limited availability of BMTs, we were unable to
investigate this possibility. However, our previous study showed
that a number of cucurbitane-type triterpenes exert similar
biological activity in stimulating GLUT4 translocation in L6
myotubes via activation of AMPK [8]. This suggests that BMT-1
is likely to be the bioactive compound by itself rather than serving
as a precursor of an active metabolite to produce the effects as
observed in the present study.
In summary, our data indicate that BMTs activate AMPK in a
manner distinct from other anti-diabetic small molecules (illus-
trated in Fig. 6). Our findings suggest that BMTs activate AMPK
through CaMKKb activation, in a calcium-independent manner,
and not through direct effects on AMPK, nor by inhibiting
mitochondrial respiration. Although CaMKKb is expressed in
tissues important to glucose and lipid metabolism, such as skeletal
muscle, liver and adipose [46], the role of CaMKKb in the onset
and treatment of insulin resistance and T2D is yet to be fully
explored. By showing that BMTs increase AMPK activity through
CaMKKb, we provide a proof-of-concept for triterpenoids, which
are abundant in the plant kingdom [44], as an attractive source of
novel AMPK activators with anti-diabetic efficacy mediated by the
upstream kinase CaMKKb.
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Figure 6. Illustration of the activation of AMPK by BMTs. BMTs
activate AMPK via CaMKKb independent of LKB1 and mitochondrial
respiration. This mechanism is different from those of other anti-
diabetic small molecules like metformin, TZDs, berberine or Abbott
Compound (A-769662).
doi:10.1371/journal.pone.0062309.g006
Tetracyclic Triterpenoids Activate CaMKK
PLOS ONE | www.plosone.org 8 April 2013 | Volume 8 | Issue 4 | e62309
References
1. Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of
diabetes for 2010 and 2030. Diabetes Res Clin Pract 87: 4–14.
2. Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, et al. (2010) Global
healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract
87: 293–301.
3. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, et al. (2007) Systematic review:
comparative effectiveness and safety of oral medications for type 2 diabetes
mellitus. Ann Intern Med 147: 386–399.
4. Fuangchan A, Sonthisombat P, Seubnukarn T, Chanouan R, Chotchaisuwat P,
et al. (2011) Hypoglycemic effect of bitter melon compared with metformin in
newly diagnosed type 2 diabetes patients. J Ethnopharmacol 134: 422–428.
5. Day C, Cartwright T, Provost J, Bailey CJ (1990) Hypoglycaemic effect of
Momordica charantia extracts. Planta Med 56: 426–429.
6. Chaturvedi P, George S (2010) Momordica charantia maintains normal glucose
levels and lipid profiles and prevents oxidative stress in diabetic rats subjected to
chronic sucrose load. J Med Food 13: 520–527.
7. Wang ZQ, Zhang XH, Yu Y, Poulev A, Ribnicky D, et al. (2011) Bioactives
from bitter melon enhance insulin signaling and modulate acyl carnitine content
in skeletal muscle in high-fat diet-fed mice. J Nutr Biochem 22: 1064–1073.
8. Tan MJ, Ye JM, Turner N, Hohnen-Behrens C, Ke CQ, et al. (2008)
Antidiabetic activities of triterpenoids isolated from bitter melon associated with
activation of the AMPK pathway. Chem Biol 15: 263–273.
9. Zeng XY, Wang YP, Cantley J, Iseli TJ, Molero JC, et al. (2012) Oleanolic acid
reduces hyperglycemia beyond treatment period with Akt/FoxO1-induced
suppression of hepatic gluconeogenesis in type-2 diabetic mice. PLoS One 7:
e42115.
10. Steinberg GR, Kemp BE (2009) AMPK in Health and Disease. Physiol Rev 89:
1025–1078.
11. Cool B, Zinker B, Chiou W, Kifle L, Cao N, et al. (2006) Identification and
characterization of a small molecule AMPK activator that treats key components
of type 2 diabetes and the metabolic syndrome. Cell Metab 3: 403–416.
12. Iglesias MA, Furler SM, Cooney GJ, Kraegen EW, Ye JM (2004) AMP-
activated protein kinase activation by AICAR increases both muscle fatty acid
and glucose uptake in white muscle of insulin-resistant rats in vivo. Diabetes 53:
1649–1654.
13. Moller DE (2001) New drug targets for type 2 diabetes and the metabolic
syndrome. Nature 414: 821–827.
14. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial
infarction and death from cardiovascular causes. N Engl J Med 356: 2457–2471.
15. Turner N, Li JY, Gosby A, To SW, Cheng Z, et al. (2008) Berberine and its
more biologically available derivative, dihydroberberine, inhibit mitochondrial
respiratory complex I: a mechanism for the action of berberine to activate AMP-
activated protein kinase and improve insulin action. Diabetes 57: 1414–1418.
16. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, et al. (2006) Berberine, a
natural plant product, activates AMP-activated protein kinase with beneficial
metabolic effects in diabetic and insulin-resistant states. Diabetes 55: 2256–2264.
17. Zini R, Morin C, Bertelli A, Bertelli AA, Tillement JP (1999) Effects of
resveratrol on the rat brain respiratory chain. Drugs Exp Clin Res 25: 87–97.
18. Yin J, Gao Z, Liu D, Liu Z, Ye J (2008) Berberine improves glucose metabolism
through induction of glycolysis. Am J Physiol Endocrinol Metab 294: E148–156.
19. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, et al. (2007)
Systemic treatment with the antidiabetic drug metformin selectively impairs p53-
deficient tumor cell growth. Cancer Res 67: 6745–6752.
20. Iseli TJ, Walter M, van Denderen BJ, Katsis F, Witters LA, et al. (2005) AMP-
activated protein kinase beta subunit tethers alpha and gamma subunits via its
C-terminal sequence (186–270). J Biol Chem 280: 13395–13400.
21. Scott JW, Hawley SA, Green KA, Anis M, Stewart G, et al. (2004) CBS domains
form energy-sensing modules whose binding of adenosine ligands is disrupted by
disease mutations. J Clin Invest 113: 274–284.
22. Xiao B, Sanders MJ, Underwood E, Heath R, Mayer FV, et al. (2011) Structure
of mammalian AMPK and its regulation by ADP. Nature 472: 230–233.
23. Oakhill JS, Steel R, Chen ZP, Scott JW, Ling N, et al. (2011) AMPK is a direct
adenylate charge-regulated protein kinase. Science 332: 1433–1435.
24. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, et al. (2003) Complexes
between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/
beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2:
28.
25. Hurley RL, Anderson KA, Franzone JM, Kemp BE, Means AR, et al. (2005)
The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated
protein kinase kinases. J Biol Chem 280: 29060–29066.
26. Woods A, Dickerson K, Heath R, Hong SP, Momcilovic M, et al. (2005) Ca2+/
calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-
activated protein kinase in mammalian cells. Cell Metab 2: 21–33.
27. Zeqiraj E, Filippi BM, Deak M, Alessi DR, van Aalten DM (2009) Structure of
the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase
activation. Science 326: 1707–1711.
28. Green MF, Anderson KA, Means AR (2011) Characterization of the
CaMKKbeta-AMPK signaling complex. Cell Signal 23: 2005–2012.
29. Green MF, Scott JW, Steel R, Oakhill JS, Kemp BE, et al. (2011) Ca2+/
Calmodulin-dependent protein kinase kinase beta is regulated by multisite
phosphorylation. J Biol Chem 286: 28066–28079.
30. Iseli TJ, Oakhill JS, Bailey MF, Wee S, Walter M, et al. (2008) AMP-activated
protein kinase subunit interactions: beta1:gamma1 association requires beta1
Thr-263 and Tyr-267. J Biol Chem 283: 4799–4807.
31. Goransson O, McBride A, Hawley SA, Ross FA, Shpiro N, et al. (2007)
Mechanism of action of A-769662, a valuable tool for activation of AMP-
activated protein kinase. J Biol Chem 282: 32549–32560.
32. Scott JW, van Denderen BJ, Jorgensen SB, Honeyman JE, Steinberg GR, et al.
(2008) Thienopyridone drugs are selective activators of AMP-activated protein
kinase beta1-containing complexes. Chem Biol 15: 1220–1230.
33. Salt I, Celler JW, Hawley SA, Prescott A, Woods A, et al. (1998) AMP-activated
protein kinase: greater AMP dependence, and preferential nuclear localization,
of complexes containing the alpha2 isoform. Biochem J 334 (Pt 1): 177–187.
34. Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, et al. (2005) Calmodulin-
dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-
activated protein kinase. Cell Metab 2: 9–19.
35. Hardie DG (1999) Roles of the AMP-activated/SNF1 protein kinase family in
the response to cellular stress. Biochem Soc Symp 64: 13–27.
36. Fogarty S, Hawley SA, Green KA, Saner N, Mustard KJ, et al. (2010)
Calmodulin-dependent protein kinase kinase-beta activates AMPK without
forming a stable complex: synergistic effects of Ca2+ and AMP. Biochem J 426:
109–118.
37. Soderling TR (1999) The Ca-calmodulin-dependent protein kinase cascade.
Trends Biochem Sci 24: 232–236.
38. Erickson JR, Joiner ML, Guan X, Kutschke W, Yang J, et al. (2008) A dynamic
pathway for calcium-independent activation of CaMKII by methionine
oxidation. Cell 133: 462–474.
39. Zhu YJ, Li CP, Tang WY, Li AP, Liu QZ, et al. (2007) Single nucleotide
polymorphism of the JWA gene is associated with risk of leukemia: a case-control
study in a Chinese population. J Toxicol Environ Health A 70: 895–900.
40. Hsu C, Hsieh CL, Kuo YH, Huang CJ (2011) Isolation and identification of
cucurbitane-type triterpenoids with partial agonist/antagonist potential for
estrogen receptors from Momordica charantia. J Agric Food Chem 59: 4553–
4561.
41. Hwang YP, Kim HG, Hien TT, Jeong MH, Jeong TC, et al. (2011) Puerarin
activates endothelial nitric oxide synthase through estrogen receptor-dependent
PI3-kinase and calcium-dependent AMP-activated protein kinase. Toxicol Appl
Pharmacol 257: 48–58.
42. Filardo EJ, Quinn JA, Bland KI, Frackelton AR, Jr. (2000) Estrogen-induced
activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog,
GPR30, and occurs via trans-activation of the epidermal growth factor receptor
through release of HB-EGF. Mol Endocrinol 14: 1649–1660.
43. Balhuizen A, Kumar R, Amisten S, Lundquist I, Salehi A (2010) Activation of G
protein-coupled receptor 30 modulates hormone secretion and counteracts
cytokine-induced apoptosis in pancreatic islets of female mice. Mol Cell
Endocrinol 320: 16–24.
44. Liby KT, Yore MM, Sporn MB (2007) Triterpenoids and rexinoids as
multifunctional agents for the prevention and treatment of cancer. Nat Rev
Cancer 7: 357–369.
45. Chen X, Lou G, Meng Z, Huang W (2011) TGR5: a novel target for weight
maintenance and glucose metabolism. Exp Diabetes Res 2011: 853501.
46. Anderson KA, Means RL, Huang QH, Kemp BE, Goldstein EG, et al. (1998)
Components of a calmodulin-dependent protein kinase cascade. Molecular
cloning, functional characterization and cellular localization of Ca2+/calmod-
ulin-dependent protein kinase kinase beta. J Biol Chem 273: 31880–31889.
Tetracyclic Triterpenoids Activate CaMKK
PLOS ONE | www.plosone.org 9 April 2013 | Volume 8 | Issue 4 | e62309
